AstraZeneca plc (AZN) Stock Rating Reaffirmed by JPMorgan Chase & Co.
AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reissued by stock analysts at JPMorgan Chase & Co. in a research note issued on Friday.
AZN has been the subject of several other reports. Deutsche Bank AG restated a “buy” rating and set a GBX 5,800 ($72.46) price objective on shares of AstraZeneca plc in a research report on Friday, July 29th. Sanford C. Bernstein set a GBX 5,333 ($66.63) price target on shares of AstraZeneca plc and gave the company a “neutral” rating in a research report on Wednesday, October 19th. Berenberg Bank set a GBX 5,550 ($69.34) price target on shares of AstraZeneca plc and gave the company a “buy” rating in a research report on Thursday, August 25th. Citigroup Inc. reiterated a “buy” rating on shares of AstraZeneca plc in a research report on Wednesday, July 27th. Finally, Goldman Sachs Group Inc. set a GBX 4,000 ($49.98) price target on shares of AstraZeneca plc and gave the company a “sell” rating in a research report on Wednesday, August 10th. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of GBX 4,947.72 ($61.82).
AstraZeneca plc (LON:AZN) opened at 4350.00 on Friday. The company’s 50 day moving average is GBX 4,806.39 and its 200 day moving average is GBX 4,565.34. The company’s market cap is GBX 55.03 billion. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.